Study provides new insights on how diabetes drug works

February 10, 2017, Wiley

Many individuals with type 2 diabetes produce abnormally low levels of a gut hormone called GLP-1, which normally stimulates insulin release from the pancreas.

Now a new study shows that GLP-1 production by special cells in the gut known as L-cells can be restored in patients with recent onset type 2 diabetes following three to 12 months of treatment with liraglutide, a drug that is similar to native GLP-1.

"This study shows that chronic liraglutide therapy induces a robust enhancement of GLP-1 secretion by the body that may hold implications for the of this medication in patients," said Dr. Ravi Retnakaran, senior author of the Diabetes, Obesity and Metabolism study.

Explore further: Liraglutide doesn't affect gastric emptying in type 1 diabetes

More information: Thomas Forst et al, Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study, Diabetes, Obesity and Metabolism (2017). DOI: 10.1111/dom.12838

Related Stories

Liraglutide doesn't affect gastric emptying in type 1 diabetes

November 28, 2016
(HealthDay)—For individuals with type 1 diabetes mellitus (T1DM), liraglutide therapy does not affect the rate of gastric emptying (GE) during hypoglycemia, according to a study published online Nov. 21 in Diabetes, Obesity ...

Type 2 diabetes drug can exhaust insulin-producing cells

February 11, 2016
Long-term use of liraglutide, a substance that helps to lower blood sugar levels in patients with type 2 diabetes, can have a deteriorating effect on insulin-producing beta cells, leading to an increase in blood sugar levels. ...

Drug helps patients with diabetes lose weight

August 18, 2015
Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks ...

Liraglutide, sitagliptin have no effect on renal hemodynamics

September 9, 2016
(HealthDay)—In insulin-naive patients with type 2 diabetes, 12 weeks of treatment with liraglutide or sitagliptin has no effect on renal hemodynamics, according to a study published online Sept. 1 in Diabetes Care.

Liraglutide tops lixisenatide as add-on to metformin in T2DM

June 28, 2016
(HealthDay)—For patients with type 2 diabetes taking metformin, add-on liraglutide is more effective than lixisenatide for improving glycemic control, according to a study published online June 16 in Diabetes Care.

Protein packaging may cause the immune attacks of type 1 diabetes

November 21, 2016
Type-1 diabetes occurs when immune cells attack the pancreas. EPFL scientists have now discovered what may trigger this attack, opening new directions for treatments.

Recommended for you

Belly fat promotes diabetes under orders from liver

March 21, 2018
The fat that builds up deep in the abdomen—more than any other type of body fat—raises the risk of insulin resistance and type 2 diabetes. Researchers have known that abdominal fat becomes dangerous when it becomes inflamed ...

Consuming low-calorie sweeteners may predispose overweight individuals to diabetes

March 18, 2018
Consumption of low-calorie sweeteners could promote metabolic syndrome and predispose people to prediabetes and diabetes, particularly in individuals with obesity, a new study on human fat-derived stem cells and fat samples ...

Are high blood glucose levels an effect rather than the cause of diabetes?

March 15, 2018
Insulin resistance and elevated blood glucose levels are considered to be the cause of type 2 diabetes. However, scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now provided ...

Smoking linked with higher risk of type 2 diabetes

March 15, 2018
The prevalence of diabetes has increased almost 10-fold in China since the early 1980s, with one in 10 adults in China now affected by diabetes. Although adiposity is the major modifiable risk factor for diabetes, other research ...

Social support and machine learning are at the core of a student-developed app for people with diabetes

March 14, 2018
Diabetes is the seventh leading cause of death in the U.S., and nearly 10 percent of the population suffers from this chronic disease, according to the Centers for Disease Control and Prevention.

Toxic proteins and type 2 diabetes

March 9, 2018
Nearly a half-billion people worldwide live with type 2 diabetes. Yet despite the disease's sizeable and increasing impact, its precise causes remain murky. Current scientific thinking points to two key processes: insulin ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.